MHS
Medco Health Solutions, Inc.NYSE
MHS is defunct.
  • Apr. 2, 2012, 11:10 AM

    Express Scripts (ESRX +3.3%) completes its $29.1B purchase of Medco (MHS -1.3%) following the FTC's approval of the deal. Three senior Medco execs will join Express' top team, although that doesn't incldue Medco CEO David Snow. Despite its dispute with Express, Walgreen's (WAG +2.3%) contract with Medco will be honored.

    | Apr. 2, 2012, 11:10 AM | 1 Comment
  • Apr. 2, 2012, 8:53 AM

    After coming off of a trading halt that followed an announcement of FTC approval for the Express Scripts (ESRX)-Medco Health (MHS) merger, shares of both companies trade higher. ESRX +3.1% premarket, MHS +0.7%.

    | Apr. 2, 2012, 8:53 AM | 1 Comment
  • Apr. 2, 2012, 8:12 AM

    The FTC officially approves the Express Scripts (ESRX)-Medco (MHS) merger after word came in last week that an approval was expected. Shares of ESRX and MHS are both currently halted for trading.

    | Apr. 2, 2012, 8:12 AM
  • Mar. 29, 2012, 1:12 PM

    While Express Scripts (ERX) and Medco (MHS) hope to close their $29.1B deal next week, two pharmacy groups and nine retail pharmacy companies file a lawsuit asking a federal court to stop the transaction. However, if the government OKs the deal, the chances of the lawsuit's success aren't great, says an antitrust expert.

    | Mar. 29, 2012, 1:12 PM
  • Mar. 28, 2012, 9:06 AM

    Express Scripts (ESRX) tips off in a filing with the SEC that it expects to close its hotly contested deal to merge with Medco Health (MHS) as early as the week of April 2. Shares of MHS +5.6% premarket, ESRX +4.7%.

    | Mar. 28, 2012, 9:06 AM | 3 Comments
  • Mar. 18, 2012, 5:41 AM
    Over 25 states are investigating Express Scripts' (ESRX) proposed $29.1B acquisition of Medco (MHS) for possible antitrust violations, Bloomberg reports. Five of the states, including New York and California, are considering lawsuits to challenge the deal should the FTC approve it.
    | Mar. 18, 2012, 5:41 AM | 1 Comment
  • Mar. 13, 2012, 8:44 AM

    Express Scripts (ESRX) and Medco (MHS) are delaying the closing of their merger to give antitrust regulators extra time to review the deal which would create the largest U.S. pharmacy benefits manager, according to an SEC filing. ESRX +1.5%, MHS +1.5% premarket.

    | Mar. 13, 2012, 8:44 AM
  • Mar. 9, 2012, 1:06 PM

    The FTC is increasingly unlikely to block the Express Scripts (ESRX +1.8%)/Medco (MHS +1.7%) deal, reports the WSJ. It's not a surprise, but the stocks get a nice pop on the news.

    | Mar. 9, 2012, 1:06 PM
  • Mar. 2, 2012, 10:44 AM

    Even as nearly everyone concedes Express Scripts' (ESRX) takeover of Medco (MHS) will receive the regulatory OK, Bloomberg figures there may still be time for "a nice trade to play." If the deal closes on March 30, traders who bought the stock at yesterday’s closing price would still enjoy a 91% annualized return, far ahead of any other major current deal.

    | Mar. 2, 2012, 10:44 AM
  • Feb. 27, 2012, 9:25 AM

    Express Scripts (ESRX) moves up 3.5% premarket and Medco Health (MHS) gains 4.9% off of a report that FTC lawyers have backed the merger between the two companies.

    | Feb. 27, 2012, 9:25 AM | 2 Comments
  • Feb. 14, 2012, 3:27 PM

    Express Scripts (ESRX +4%) and Medco Health (MHS +2.9%) climb on a report the FTC is likely to approve their merger deal, although a legal challenge remains possible. The issue is likely to be decided by FTC Chairman Jon Leibowitz, who worked as Sen. Herb Kohl's leading antitrust advisor for years, market intelligence journal MLex says.

    | Feb. 14, 2012, 3:27 PM
  • Feb. 10, 2012, 8:22 AM

    Express Scripts (ESRX) prepares to tell regulators that its delivered all the requested information on the purchase of Medco Health (MHS) in a move that will trigger a 30-day FTC review of the deal. The agency can clear the deal, sue to block it, or negotiating a settlement.

    | Feb. 10, 2012, 8:22 AM
  • Feb. 7, 2012, 9:13 AM

    Shares of Medco Health (MHS) and Express Scripts (ESRX) could be poised to rebound after yesterday's report that the FTC may reject the merger deal between the two companies. While sources tell the NY Post the deal still has a better than 50% chance of FTC approval, a merger of commercial real estate data providers CoStar Group (CSGP) and LoopNet (LOOP) may be in danger.

    | Feb. 7, 2012, 9:13 AM
  • Feb. 6, 2012, 1:34 PM

    Shares of Express Scripts (ESRX -4.2%)and Medco (MHS -8.8%) sink off of a report that the FTC is gathering evidence to use in a bid to block a deal between the companies to merge. A final decision on whether or not to sue is expected from the agency by end of February or early in March.

    | Feb. 6, 2012, 1:34 PM | 2 Comments
  • Dec. 21, 2011, 9:59 AM

    Medco's (MHS -0.3%) shareholders officially approve the proposed $29B merger with Express Scripts (ESRX -0.9%), edging the firms closer to a marriage in an increasingly tough antitrust climate.

    | Dec. 21, 2011, 9:59 AM
  • Dec. 20, 2011, 3:28 PM

    AT&T's failed deal for T-Mobile shines a spotlight on the tougher antitrust climate, placing "a very firm marker that [the U.S. government is] taking antitrust enforcement very seriously." Next big deal to watch: the proposed $29B merger of Express Scripts (ESRX +3%) and Medco (MHS +2%); the latter's shares are up today but trade ~16% below the value of the ESRX offer.

    | Dec. 20, 2011, 3:28 PM